CT
BMRN icon

Colonial Trust’s BioMarin Pharmaceuticals BMRN Stock Holding History

Colonial Trust’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.2K Buy
+56
New +$3.07K ﹤0.01% 962
2025
Q1 		– Sell
-302
Closed -$19.9K – 1130
2024
Q4 		$19.9K Buy
+302
New +$20.2K ﹤0.01% 806
2023
Q2 		– Sell
-57
Closed -$5.43K – 942
2023
Q1 		$5.43K Buy
+57
New +$5.91K ﹤0.01% 741

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Colonial Trust's BMRN Position: Q2 2026 in Review

Colonial Trust opened a new position in BioMarin Pharmaceuticals (BMRN) in Q2 2026: 56 shares worth $3.2K. The stake represents ﹤0.01% of the portfolio and ranks #962 among its holdings. This is a return to the name: Colonial Trust previously reported a position in BMRN as recently as Q4 2024.

Colonial Trust first reported a position in BMRN in Q1 2023 and has held it in 3 quarters since. The position peaked at $19.9K in Q4 2024. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Colonial Trust held 56 shares of BioMarin Pharmaceuticals worth $3.2K as of Q2 2026.
  • BioMarin Pharmaceuticals was a new Colonial Trust position in Q2 2026.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Colonial Trust's portfolio in Q2 2026, its #962 holding.
  • Colonial Trust first reported a position in BioMarin Pharmaceuticals in Q1 2023 and has held it in 3 quarters since.
  • Colonial Trust's BioMarin Pharmaceuticals position peaked at $19.9K in Q4 2024.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Colonial Trust's 13F filing for Q2 2026, filed 11 Aug 2026.